Manchester, UK. 6^th March 2017 –

Elucigene Diagnostics announced today that is has been named as winner for the MEDILINK NW Innovation Award, sponsored by the Innovation Agency, for the company’s flagship Cystic Fibrosis family of population specific diagnostic assays.

Expedient diagnosis and treatment of newborns suffering from Cystic Fibrosis offers the greatest quality and longevity of life. Newborn Screening (NBS) using traditional methods results in approximately 20% of CF affected individuals requiring Sanger Sequencing of the whole CFTR gene, which is costly, labour intensive and challenging to interpret and report.

CFEU2 enables 95% of patients to be diagnosed within 1 day (Example for UK population), providing a cost effective assay that is simple to use and interpret, reports only clinically relevant findings.

Implementation of the CFEU2 product has reduced diagnostic times, expenditure and laboratory labour in relation to NBS CF testing.

Following the awards ceremony held last week, Operations Director Dr Greg Fitzgibbon said “We are very proud to have accepted this award, given the excellent calibre of technology coming from the region. This award recognises the outstanding and innovative work carried out by the team hear at Elucigene, which puts patients, clinicians and laboratory teams at the heart of our assay design”.

“We have seen exceptional uptake of the CF-EU assay and its family of regional specific add on panels, with over 40 countries now using the technology, the assay is now the market leader in many regions” added Sales and Marketing Director, Mark Street-Docherty.